Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 1,773

Deploying “AI for Good” In The Life Sciences — Tom Lawry, National Director for Artificial Intelligence, Health & Life Sciences, Microsoft, joins me on ideaXme to discuss how they are deploying artificial intelligence “at scale”, across the major organizations responsible for delivery quality, next generation healthcare to millions of patients and customers — #Ideaxme #Microsoft #ArtificialIntelligence #MachineLearning #DeepLearning #Health #Healthcare #Wellness #Medicine #Pharmacy #Hospitals #Nursing #Insurance #Diagnostics #Data #Moonshots #Biotechnology #Longevity #LifeExtension #Aging #IraPastor #Bioquark #Regenerage

Ira Pastor, ideaXme life sciences ambassador, interviews Tom Lawry, National Director for Artificial Intelligence — Health & Life Sciences at Microsoft.

Ira Pastor Comments:

A set of tools that we have been hearing quite a bit about (and discussed a bit on the show) in recent years is the triad of artificial intelligence, machine learning, and deep learning and their respective applications (primarily in the drug discovery and development processes), in terms how university labs and startups are using some of these tools to better guide the rational drug design process, or more appropriately select patients for a clinical trial, per the field of personalized medicine.

Today we are going to go to the far end of the spectrum, to a view of the potential of these tools at “scale”, when they need to be deployed across the mega enterprises responsible for delivery quality, next generation healthcare to millions of customers.

Continue reading “Tom Lawry Talks of Machine Learning and Microsoft AI For Good in Healthcare” | >

Worldwide, 800,000 people die annually due to suicide (1 every 40 seconds) — There are more than twice as many suicides as homicides — Suicide is now the 10th leading cause of death in the US, and the 2nd leading cause of death among individuals between ages of 10 and 34 — Dr. Christine Moutier, M.D., Chief Medical Officer, American Foundation for Suicide Prevention, joins me on ideaXme to discuss her organization’s work in suicide prevention science and impacting these disturbing trends — #Ideaxme #Suicide #Depression #MentalHealth #Psychiatry #Anxiety #Stress #Trauma #Coronavirus #Burnout #WellBeing #Resilience #Health #Wellness #Longevity #Aging #IraPastor #Bioquark #Regenerage National Institute of Mental Health National Academy of Medicine.

Ira Pastor, ideaXme life sciences ambassador and founder of Bioquark, interviews Dr. Christine Moutier, MD, Chief Medical Officer, at the American Foundation for Suicide Prevention (AFSP).

Ira Pastor comments:

According to the World Health Organization (WHO), close to 800,000 people die due to suicide every year, which is one person every 40 seconds. Suicide is a global phenomenon and occurs throughout the lifespan, and there are indications that for each adult who died by suicide, there may have been more than 20 others attempting suicide.

According to the U.S. Centers for Disease Control and Prevention (CDC) “Leading Causes of Death Report”, in 2017 suicide was the tenth leading cause of death overall in the United States, claiming the lives of over 47,000 people; Suicide was the second leading cause of death among individuals between the ages of 10 and 34, and the fourth leading cause of death among individuals between the ages of 35 and 54. There were more than twice as many suicides in the United States as there were homicides.

Continue reading “Dr Christine Moutier talks of Mental Health Awareness, Suicide Prevention and Building Resilience” | >

WOW! A reduction in air pollution means residents in Nepal can see Mount Everest from over 120 miles away for the first time in decades. https://bit.ly/3bPjlNt

An incredible photo shows Mount Everest visible for the first time in decades from the Nepalese city of Kathmandu.

A coronavirus lockdown-related reduction in air pollution has made the famous visible from the city 124 miles away, according to the Nepali Times. The photo was taken by Abhushan Gautam from the Kathmandu Valley on May 10.

Some 427 coronavirus cases have been diagnosed in Nepal, and COVID-19 has accounted for two deaths in the country, according to data from Johns Hopkins University.

Read more | >

Check out Megaprojects: https://www.youtube.com/channel/UC0woBco6Dgcxt0h8SwyyOmw

→Subscribe for new videos every day!

Find more lists at: http://www.toptenz.net
Our other YouTube Channels:
Biographics: https://www.youtube.com/channel/UClnDI2sdehVm1zm_LmUHsjQ/
Geographics: https://www.youtube.com/channel/UCHKRfxkMTqiiv4pF99qGKIw/

Business inquiries to [email protected]

Read more | >

Cross-posted from U.S. Food and Drug Administration

[On July 2, 2020], the U.S. Food and Drug Administration approved Rukobia (fostemsavir), a new type of antiretroviral medication for adults living with HIV who have tried multiple HIV medications and whose HIV infection cannot be successfully treated with other therapies because of resistance, intolerance or safety considerations.

“This approval marks a new class of antiretroviral medications that may benefit patients who have run out of HIV treatment options,” said Jeff Murray, M.D., deputy director of the Division of Antivirals in the FDA’s Center for Drug Evaluation and Research. “The availability of new classes of antiretroviral drugs is critical for heavily treatment-experienced patients living with multidrug resistant HIV infection—helping people living with hard-to-treat HIV who are at greater risk for HIV-related complications, to potentially live longer, healthier lives.”

Read more | >

Bioengineering.

There is currently no vaccine or cure towards COVID-19. It is predicted the development of a safe and effective vaccine to prevent COVID-19 will take 12 to 18 months, by which time hundreds of thousands to millions of people may have been infected. With a rapidly growing number of cases and deaths around the world, this emerging threat requires a nimble and targeted means of protection.

Could CRISPR be the next virus killer? To address this global pandemic challenge, we are developing a genetic vaccine that can be used rapidly in healthy and patients to greatly reduce the coronavirus spreading. We developed a safe and effective CRISPR system to precisely target, cut and destroy COVID-19 virus and its genome, which stops coronavirus from infecting the human lung.

We’ve shown that the CRISPR system can reduce 90% of coronavirus load in human cells. It can also protect humans against essentially 90% of all current and emerging coronaviruses. The project is ongoing, and we are working around the clock towards getting an actual product by combing our CRISPR method with an inhaler-based delivery device.

Read more | >

Findings In this bayesian randomized clinical trial that included 403 patients and was stopped early after results from another trial were released, treatment with a 7-day fixed-dose course of hydrocortisone or shock-dependent dosing of hydrocortisone, compared with no hydrocortisone, resulted in 93% and 80% probabilities of superiority, respectively, with regard to the odds of improvement in organ support–free days within 21 days.

Objective To determine whether hydrocortisone improves outcome for patients with severe COVID-19.

Design, Setting, and Participants An ongoing adaptive platform trial testing multiple interventions within multiple therapeutic domains, for example, antiviral agents, corticosteroids, or immunoglobulin. Between March 9 and June 17, 2020, 614 adult patients with suspected or confirmed COVID-19 were enrolled and randomized within at least 1 domain following admission to an intensive care unit (ICU) for respiratory or cardiovascular organ support at 121 sites in 8 countries. Of these, 403 were randomized to open-label interventions within the corticosteroid domain. The domain was halted after results from another trial were released. Follow-up ended August 12, 2020.

Interventions The corticosteroid domain randomized participants to a fixed 7-day course of intravenous hydrocortisone (50 mg or 100 mg every 6 hours) (n = 143), a shock-dependent course (50 mg every 6 hours when shock was clinically evident) (n = 152), or no hydrocortisone (n = 108).

Read more | >

Providence, R.I. — The federal government has told states to prepare for a coronavirus vaccine to be ready to distribute by Nov. 1.

The timeline raised concern among public health experts about an “October surprise” — a vaccine approval driven by political considerations ahead of a presidential election, rather than science.

In a letter to governors dated Aug. 27, Robert Redfield, director of the U.S. Centers for Disease Control and Prevention, said states “in the near future” will receive permit applications from McKesson Corp., which has contracted with CDC to distribute vaccines to places including state and local health departments and hospitals.

Read more | >